Fundraising Fox

Naurex

Evanston, US · 4 known investors

Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.

Biotech

Founders & leadership

JR
Joseph R. MoskalFounder
AK
Amin KhanExecutive
JS
James SchulzExecutive
RM
Ronald M. BurchExecutive
NR
Norbert RiedelExecutive
AK
Ashish KhannaExecutive
MS
Mitchell S. BloomNamed on SEC filing

Board

KJ
Kenneth J. WidderBoard director
TG
Terry GouldBoard director
RJ
Robert J. HombachBoard director
WH
Wilbur H. GantzBoard director
IF
Ian FerrierBoard director

Investors · 4

Cota CapitalSan Francisco
EcoR1 CapitalSan Francisco
Latterell Venture PartnersSan Ramon · $50K – $10M
Sofinnova VenturesMenlo Park · $100K – $15M

Reported raises · per SEC filings

Form D private placements

$105M disclosed across 2 rounds · 2014

▶$80MraisedDec 2014 · 61 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Kenneth J. WidderDirector
  • Terry P. GouldDirector
  • Robert J. HombachDirector
  • Mitchell S. BloomExecutive Officer
  • Wilbur H. GantzDirector
  • Norbert G. RiedelExecutive Officer, Director
  • Ashish KhannaExecutive Officer
  • Ronald M. BurchExecutive Officer
  • Mohamed Amin KhanExecutive Officer
  • Derek A. SmallDirector
  • James SchulzExecutive Officer
  • Ian R. FerrierDirector
  • Joseph R. MoskalExecutive Officer
Amount sold
$80M
First sale
Nov 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedMay 2014 · 40 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Amin KhanExecutive Officer
  • Robert J. HombachDirector
  • Wilbur H. GantzDirector
  • James SchulzExecutive Officer
  • Kenneth J. WidderDirector
  • Mitchell S. BloomExecutive Officer
  • Joseph R. MoskalExecutive Officer
  • Ronald M. BurchExecutive Officer
  • Ian FerrierDirector
  • Norbert RiedelExecutive Officer, Director
  • Terry GouldDirector
  • Ashish KhannaExecutive Officer
Amount sold
$25M
First sale
May 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$197.6K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Naurex do?
Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.
Who founded Naurex?
Naurex was founded by Joseph R. Moskal.
Who are Naurex's investors?
Naurex's investors include Cota Capital, EcoR1 Capital, Latterell Venture Partners, Sofinnova Ventures.
How much funding has Naurex raised?
Naurex has disclosed $105M raised across 2 rounds.
Where is Naurex headquartered?
Naurex is headquartered in Evanston, US.